Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2019

View Archived Issues

Glial dysfunction is part of chemo brain

TLRs in DIO

"R-AI-diologist" can outperform radiologists in lung cancer screening

In infection, T cells are cachexia drivers

Food antigens drive IgE antibody elevation if no commensals present

SNG-001 for virus-induced exacerbations of lung disease

Enrollment opens in phase III study of HLX-10 in esophageal squamous cell carcinoma

Soligenix obtains support to study IDRs as bacterial threat countermeasures

Mutation in mevalonate kinase found in porokeratosis ptychotropica

Integral Molecular achieves milestone in Daiichi Sankyo immuno-oncology collaboration

Ziopharm and NCI sign T-cell technology licensing agreement

Bristol-Myers Squibb patents farnesoid X receptor agonists

ProMIS identifies antibody candidates that selectively bind toxic oligomers of tau for Alzheimer's

Researchers develop new murine model of dystrophic epidermolysis bullosa-squamous cell carcinoma

AbbVie and Calico Life Sciences jointly describe EIF2B activators

Idorsia prepares and tests antibacterial compounds

P2X3 and/or P2X2/3 receptor antagonists described in Beijing Tide Pharmaceutical patent

AiCuris reports agents for the treatment of HBV infections

In vivo antitumoral activity seen with mixture of cytokine-encoding mRNAs

FDA approves Revlimid with rituximab for previously treated FL and marginal zone lymphoma

Zynerba initiates phase II trial of Zygel to treat behavioral symptoms in 22q11.2 deletion syndrome

Eli Lilly divulges BTK inhibitors in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...